免疫功能受损宿主重症肺炎诊断与治疗中国专家共识
免疫功能受损宿主数量逐年增加,感染后重症肺炎风险显著升高且病死率明显高于免疫正常人群,但国内外缺乏针对该人群的专门指南或共识。中华医学会呼吸病学分会与中国抗癌协会肿瘤呼吸病学专业委员会组织多学科专家,采用GRADE框架围绕14个关键临床问题制定本共识,涵盖定义与分类、诊断与治疗流程、病原学、抗感染治疗、呼吸支持及免疫调节等方面。
要点
- 免疫功能受损宿主定义为对病原体免疫应答显著减弱或缺失者,分为原发性和继发性,评估需结合基础疾病与免疫学指标。
- 该人群重症肺炎诊断采用2016年中国社区获得性肺炎(CAP)指南标准,初诊时评估病情严重度与免疫状态,住院阈值可适当降低(1C)。
- 鉴别感染性与非感染性肺部浸润推荐多维方法,整合临床、影像与微生物学资料,必要时行组织病理活检和/或多学科团队(MDT)会诊(1A)。
核心结论
- 本共识围绕免疫功能受损宿主重症肺炎的14个关键临床问题,采用GRADE框架系统评价证据并形成推荐,旨在规范临床实践、支持循证决策并最终改善中国免疫功能受损重症肺炎患者的结局。
研究设计与样本
- 中华医学会呼吸病学分会(CTS)与中国抗癌协会(CACA)肿瘤呼吸病学专业委员会召集中国呼吸与危重症医学、感染病学等相关领域多学科专家制定本共识。
- 专家组系统评价证据并采用推荐分级的评估、制定与评价(GRADE)框架形成推荐,共识涉及14个关键临床问题。
主要发现
- 近年来免疫功能受损宿主人群稳步增加,临床证据表明其感染后发生重症肺炎的风险显著升高,病死率明显高于免疫正常个体。
- 目前缺乏针对该人群重症肺炎管理的专门国家或国际指南或专家共识。
- 免疫功能受损宿主肺炎的核心病原体通常与免疫正常宿主相似,但病原体分布更多样,机会性病原体和混合感染患病率更高(见表5和图1A)。
关键数值与推荐
- 推荐1:免疫功能受损宿主定义为因各种内在或外在因素对病原体免疫应答显著减弱或缺失的患者,免疫受损状态分为原发性和继发性,评估应结合基础疾病与可获得的免疫学参数。
- 推荐2:免疫功能受损宿主重症肺炎依据2016年中国社区获得性肺炎(CAP)指南标准诊断,初诊时评估病情严重度和免疫状态以评估风险并指导治疗决策,该人群住院阈值可适当降低(1C)。
- 推荐3:推荐采用多维方法鉴别免疫功能受损宿主重症肺炎与非感染性肺部浸润,整合临床、影像和微生物学资料,必要时行组织病理活检和/或多学科团队(MDT)会诊,详细诊疗流程见图1(1A)。
- 推荐5:高质量临床标本是病原学诊断所必需,疑似感染后推荐早期采样行微生物学检测,采样方式应根据患者病情和临床团队经验个体化(1B)。
- 推荐6:对免疫功能受损宿主重症肺炎,推荐在经验性治疗前或同时进行全面的微生物学检测,以尽早识别病原体并指导治疗策略(1A)。
临床怎么用
- 初诊时即应评估病情严重度和免疫状态,该人群住院阈值可适当降低(1C)。
- 疑似感染后早期采样行微生物学检测,经验性治疗前或同时进行全面的微生物学检测以尽早识别病原体(1B、1A)。
- 经验性抗感染方案应覆盖耐药革兰阴性菌和革兰阳性菌,存在危险因素时扩大覆盖(1A)。
- 不需要立即插管者首选无创呼吸支持,可选HFNO或NPPV(1A)。
- 应评估免疫状态以指导个体化免疫调节策略(1B)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「局限性」,故未列出该栏;全文请点「阅读原文」。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Zhonghua Jie He He Hu Xi Za Zhi. 2026 Feb 12;49(2):113-130. doi: 10.3760/cma.j.cn112147-20250729-00449. ABSTRACT The population of immunocompromised hosts has steadily increased in recent years. Clinical evidence indicates that these individuals are at a significantly higher risk of developing severe pneumonia following infection, with the mortality rates markedly higher than those observed in immunocompetent individuals. However, there is currently a lack of specific national or international guidelines or expert consensus addressing the management of severe pneumonia in this population. To address this unmet need, the Chinese Thoracic Society (CTS) of the Chinese Medical Association and the Oncology Respiratory Disease Committee of China Anti-Cancer Association (CACA) convened a multidisciplinary panel of experts from respiratory and critical care medicine, infectious diseases, and related fields in China to develop the present consensus.This consensus addresses 14 key clinical questions, covering topics such as the definition and classification of immunocompromised hosts, and the diagnosis and treatment of severe pneumonia in this high-risk group. The panel systematically reviewed evidence and formulated recommendations using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) framework. The resulting consensus aims to standardize clinical practice, support evidence-based decision-making, and eventually improve outcomes for immunocompromised patients with severe pneumonia in China. Question 1: Definition and classification of immunocompromised Hosts. Recommendation 1 : An immunocompromised host is defined as a patient with a significantly weakened or absent immune response to pathogens owing to various intrinsic or extrinsic factors. The immunocompromised status is categorized as either primary or secondary. This assessment should integrate the patient's underlying conditions with available immunological parameters. Question 2: What are the diagnostic criteria for severe pneumonia in immunocompromised hosts, and which indicators are recommended for severity assessment? Recommendation 2 : Severe pneumonia in immunocompromised hosts is diagnosed based on the criteria outlined by the 2016 Chinese guidelines for community-acquired pneumonia (CAP). Disease severity and immune status should be assessed at initial diagnosis to evaluate risk and guide treatment decisions. Hospitalization thresholds may be appropriately reduced in this population (1C).Question 3: What are the diagnostic and therapeutic workflows for severe pneumonia in immunocompromised hosts, and how should infectious pneumonia be distinguished from non-infectious pulmonary infiltrates?Recommendation 3: A multidimensional approach is recommended for differentiating severe pneumonia from non-infectious pulmonary infiltrates in immunocompromised hosts. Clinical, radiological, and microbiological data should be integrated. When necessary, histopathological biopsy and/or multidisciplinary team (MDT) consultation should be performed. The detailed diagnostic and therapeutic workflow are illustrated in Figure 1 (1A).Question 4: What are the major pathogens causing pneumonia in immunocompromised hosts, and how does pathogen distribution differ across immunosuppressive states?Recommendation 4: The core pathogens causing pneumonia in immunocompromised hosts are usually similar to those in immunocompetent hosts. However, pathogen distribution is more diverse, with immunocompromised hosts showing a higher prevalence of opportunistic pathogens and mixed infections (Table 5 and Figure 1A).Question 5: What are the recommended timings and methods for obtaining clinical specimens from immunocompromised hosts?Recommendation 5: High-quality clinical specimens are necessary for etiological diagnosis. Once infection is suspected, early sampling for microbiological testing is recommended. The sampling approach should be individualized based on the patient's condition and the clinical team's experience (1B).Question 6: How to choose diagnostic methods for pathogen identification in immunocompromised hosts with pneumonia?Recommendation 6: For immunocompromised hosts with severe pneumonia, comprehensive microbiological testing should be performed before or concurrently with empirical therapy to identify pathogens as early as possible and guide treatment strategies (1A).Question 7: What are the principles of anti-infective therapy for severe pneumonia in immunocompromised hosts?Recommendation 71. Initial empirical therapy should target drug-resistant Gram-negative and Gram-positive bacteria, with expansion of coverage when risk factors are present (1A).2. For ventilator-associated pneumonia (VAP), combination regimens that include β-lactams are recommended (1A).3. Echinocandins are preferred for treating invasive pulmonary candidiasis, and a switch to azoles may be considered when appropriate (1A).4. Empirical coverage for cytomegalovirus pneumonia is recommended for patients developing bilateral interstitial pneumonia shortly after lung transplantation or hematopoietic stem cell transplantation (1A).Question 8: What factors should be considered when selecting empirical anti-infective therapy for severe pneumonia in immunocompromised hosts?Recommendation 8: Empirical therapy should be selected based on the type and degree of immunodeficiency, healthcare exposure, risk of antimicrobial resistance, severity of infection, microbiological findings, treatment response, and preventive strategies (1A).Question 9: What are the recommended treatment durations for different pathogens in severe pneumonia among immunocompromised hosts?Recommendation 9: Treatment duration primarily depends on clinical presentation, radiographic changes, severity of infection, pathogen resistance profile, and the immune status of patients (1A).Question 10: Which respiratory support strategies should be prioritized for immunocompromised hosts with severe pneumonia complicated by respiratory failure?Recommendation 10: Noninvasive respiratory support is preferred for immunocompromised hosts with severe pneumonia and respiratory failure who do not require immediate intubation. High-flow nasal oxygen (HFNO) or noninvasive positive-pressure ventilation (NPPV) may be selected (1A).Question 11: When is tracheal intubation most appropriate for immunocompromised hosts with severe pneumonia?Recommendation 11: The timing of tracheal intubation in immunocompromised hosts is usually similar to that in immunocompetent hosts (1A).Question 12: When should extracorporeal membrane oxygenation (ECMO) be initiated in immunocompromised hosts with severe pneumonia and respiratory failure?Recommendation 12: The timing of ECMO initiation should be determined based on the same criteria as those used for immunocompetent hosts (1A).Question 13: For immunocompromised patients with severe pneumonia and respiratory failure, is early extubation followed by NPPV or HFNO a viable option?Recommendation 13: Early extubation followed by NPPV or HFNO can be actively considered for immunocompromised patients with severe pneumonia complicated by respiratory failure. In the absence of contraindications to NPPV, NPPV may be attempted as the initial post-extubation strategy (1A).Question 14: What recommendations are there for immunomodulatory therapy in immunocompromised hosts with severe pneumonia?Recommendation 14: Immunomodulation is an important component of therapy in immunocompromised hosts with severe pneumonia. Immune status should be assessed to guide individualized immunoregulatory strategies (1B).
引用
- 指南共识 · 肺炎:Chinese expert consensus on the diagnosis and treatment of severe pneumonia in immunocompromised hosts
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。